What's Happening?
Indivior has presented new real-world evidence at the AMCP Nexus 2025 conference, demonstrating the clinical and economic benefits of adherence to monthly injectable buprenorphine, known as SUBLOCADE,
for treating opioid use disorder (OUD). The data shows that patients with high adherence to SUBLOCADE experienced lower relapse rates, reduced healthcare resource utilization, and fewer infectious disease complications compared to those with low adherence. These findings suggest that SUBLOCADE can improve patient outcomes and offer value to healthcare payors by reducing costs associated with emergency and inpatient care.
Why It's Important?
The evidence supporting SUBLOCADE's effectiveness in managing OUD is significant for addressing the ongoing opioid crisis in the U.S. By reducing relapse rates and healthcare utilization, this treatment can alleviate the burden on healthcare systems and improve the quality of life for individuals with OUD. The economic benefits highlighted in the study also make a compelling case for broader adoption of SUBLOCADE, potentially influencing policy decisions and insurance coverage for OUD treatments. This aligns with efforts to provide comprehensive, evidence-based care for individuals struggling with opioid addiction.
